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Introduction: Pre-transplantation anti-major histocompatibility
complex class-I related chain A (MICA) sensitization is an uncom-
mon event and its role in kidney graft evolution is not completely
deﬁned. Even when kidney allografts are well matched for HLA as
in living related transplant and anti-HLA antibodies are not
detected, graft rejection can still occur. Anti MICA antibody is
reportedly associated with poor transplant outcomes and a high
risk of acute and chronic rejection in renal transplantation.
Methods: A retrospective study of patients undergone living renal
transplantation between years 2000-2014 was performed. Recipients
were classiﬁed in two groups, pre-transplantation Anti MICA
antibody positive group (n¼17) and antibody negative comparison
group (n¼17). Patients with anti HLA antibodies were excluded
and only isolated MICA positive patients were included in the
study group. Both groups were comparable in recipient age, donor
age, donor relation, HLA and immunosuppression.
Results: Patients with pre transplant MICA antibody positivity
were associated with increased acute rejection rate as compared to
comparison group (47% vs 11.7 %, p value¼ 0.02). Renal function
in MICA positive group and comparison group were comparable
over a mean follow up of 6.5 years (mean creatinine 1.58 vs 1.53 mg/
dl). Rate of chronic rejection was same in both groups (5.8%). No
patient loss or graft loss occurred in either group over mean follow
up of 6.5 years.
Conclusions: Isolated Anti MICA antibody positivity is uncommon
event. Pre transplant anti MICA antibody positivity is associated
with increased acute rejection rates. However chronic rejection
rates and renal function are comparable in both groups. Thus our
study emphasizes that MICA antibody positive patients may
require more aggressive immunosuppression. Role of desensitiza-
tion has to be deﬁned.
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Introduction: Current histologic processing of renal biopsies pro-
vides limited information about immune mechanisms causing kid-
ney injury and disease activity. To overcome this we developed a
protocol to reduce a fraction of a renal biopsy to single cells for
multicolor ﬂow cytometry and for capture and quantitation of cy-
tokines present in the biopsy. Using this technique we deﬁne newKidney International Reports (2016) 1, S1–S22criteria for evaluating rejection and renal inﬂammation that is
useful for directing therapy.
Methods: A third of a standard kidney biopsy core is reduced to a
cell suspension amenable for multi-color ﬂow cytometry without
losing cells or epitopes of interest. The resulting supernatant is used
for measuring cytokines with high-sensitivity Milliplex reagents on
a Luminex platform. After analysis of hundreds of transplant bi-
opsies we now generate clinically useful reports describing
lymphocyte subsets, endothelial antibody and eculizumab binding
and IL-6, IL-8 and IL-10 levels.
Results:A ratio of CD8+ to CD4+ T lymphocytes greater than 1.2 in
transplanted allografts is associated with rejection, even before it is
apparent by microscopy. Elevated numbers of CD45 leukocytes and
higher levels of IL-6, IL-8 and IL-10 within the biopsy indicate
more severe injury.
Peripheral blood T lymphocyte subsets do not correlate with
those found within the renal allograft. In addition, lymphocytes
within the kidney express variable degree of activation based on
expression of CD69 and HLA-DR, while these markers are low or
absent on peripheral blood lymphocytes.
Antibody binding to renal microvascular endothelial cells can
be measured by cytometry and corresponds to antibody-mediated
forms of allograft rejection. Eculizumab binding to endothelial cells
suggests complement activation, which may be independent of
bound antibody, or associated with it.
Conclusions: Assessment of leukocyte subsets, renal microvascular
endothelial properties and measurement of cytokines within a renal
biopsy enhance understanding of pathogenesis, provide disease
activity markers and identify potential targets for therapy.
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Introduction: Reports on the utility of rituximab in difﬁcult
nephrotic syndrome (NS) have been varied. We retrospectively
analyzed the outcome of rituximab, used in a multi centre cohort of
difﬁcult nephrotic syndrome (NS) from Eastern India.
Methods: Data was collected for all children with NS who received
rituximab from May 2011 to Nov 2015. Steroid resistant (SRNS) and
steroid dependent / frequently relapsing (SDNS /FRNS) were
identiﬁed as per standard deﬁnition. Complete response (CR) for
SRNS was deﬁned as normalization of serum albumin and urinary
protein creatinine ratio (UPCR) whereas for partial response (PR);
50% improvements in these parameters along with albumin at last
follow up $ 2gm/dl. In cases of SDNS/FRNS; CR was deﬁned as
stoppage of steroid and absence of relapses for at least a year and PR
as discontinuation of steroid without any relapses for at least six
month or reduction in steroid threshold by at least 50%.
Results: 34 children (56 % male) were identiﬁed (SRNS ¼12, SDNS/
FRNS ¼22). Among SRNS all had failed steroid (S), mycophenola-
te(M) as well as calcineurin inhibitor (CNI) except two who were
CNI naïve prior to rituximab. Among the SDNS/ FRNS group, 11
(50%) children had failed all drugs (S, M, CNI & cyclophospha-
mide) and the rest were not exposed to CNI. Majority were minimalS1
